Publication of the Breast Cancer Study Abstract to be presented at ASCO 2016

1.Date of occurrence of the event:2016/05/19
2.Name of the company: OBI Pharma, Inc.
3.Relationship to the Company (please enter ”head office” or ”affiliate
company”): The Company head office
4.Reciprocal shareholding ratios:N/A
5.Name of the reporting media:N/A
6.Content of the report:N/A
7.Cause of occurrence: OBI Pharma published the abstract of OBI Pharma’s
clinical study, entitled, ”A Double-blind, Randomized Trial of Active
Immunotherapy With Globo H-KLH (OPT-822) in Subjects With Metastatic
Breast Cancer” (Abstract: Randomized Phase 2/3 Trial of Active Immunotherapy
With OPT-822/OPT-821 in Patients With Metastatic Breast Cancer) on the
website of American Society of Clinical Oncology (ASCO).
8.Countermeasures: Ensure the general public is able to easily access the full
text of the abstract at the following
URL:http://abstract.asco.org/176/AbstView_176_168513.html
Here is the link to the Chinese version of the Abstract
http://www.obipharma.com/index.aspx?lang=chi&fn=news_content&no=72
9.Any other matters that need to be specified:None